Background: Anecdotal observations suggest that retinoic acid may be effective in mild rosacea. Aim: Our aim was to investigate, by an exploratory clinical and instrumental study, the effects of a topical formulation with the retinoic acid precursor retinaldehyde, in patients with vascular signs of facial rosacea. Methods: Female patients were treated with a 0.05% retinaldehyde cream that was applied once daily for 6 months. Clinical assessments of persistent erythema and telangiectasia were performed every month, using a 4-point severity score (absent to severe). The clinical response for each parameter was defined as a decrease of at least 1 grade in the severity score. In addition, erythema was further evaluated by measurement of the a* parameter, using a spectrophotometer on lesional and nonlesional areas. Results: A total of 23 women comprised the study population. At baseline, 10 patients had diffuse erythema, 3 patients had isolated telangiectasia and 10 patients had both. During retinaldehyde treatment, a clinical response was revealed in about 75% of the patients with erythema, after 5 months (p < 0.05). Similarly, isolated telangiectasia responded to retinaldehyde, although to a lesser extent and after a longer period of treatment (46% responders after 6 months, nonsignificant). Using the spectrophotometer, the a* parameter diminished in patients with erythema by about 15%, after 2 months of treatment (p = 0.001). Conclusion: This study indicates that retinaldehyde has beneficial effects on the vascular component of rosacea.

Kligman AM: Topical tretinoin for rosacea: A preliminary report. J Dermatol Treat 1993;4: 71–73.
Saurat JH, Didierjean L, Masgrau E, Piletta PA, Jaconi S, Châtellard-Gruaz D, Masouyé I, Salomon D, Sigenthaler G: Topical retinaldehyde on human skin: Biologic effects and tolerance. J Invest Dermatol 1994;103:770–774.
Katz AM: Rosacea: Epidemiology and pathogenesis. J Cutan Med Surg 1998;2(suppl 4): 5–10.
Singer MI: Drug therapy of rosacea: A problem-directed approach, J Cutan Med Surg 1998;2(suppl 4):20–23.
Gregory AE, Levine N, Kligman AM: A Comparison of the efficacy of topical tretinoin and low-dose oral isotretinoin in rosacea. Arch Dermatol 1994;130:319–324.
Creidi P, Vienne MP, Ochonisky S, Lauze C, Turlier V, Lagardde JM, Dupuy P: Profilometric evaluation of photodamage after topical retinaldehyde and retinoic acid treatment. J Am Acad Dermatol 1998;39:960–965.
Lachgar S, Charveron M, Aries MF, Gall Y, Bonafé JL: Inhibitory effects of retinoids on VEGF production by cultured human skin keratinocytes (abstract). J Invest Dermatol 1997; 109:455.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.